Overview

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

Status:
Unknown status
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.
Phase:
Phase 4
Details
Lead Sponsor:
Yanqing Li
Treatments:
Amoxicillin
Anti-Infective Agents
Clarithromycin
Furazolidone
Levofloxacin
Ofloxacin
Tetracycline
Tinidazole